$280.41
-0.37-0.13%
Last update: Nov 11, 7:49 PM
Johnson & Johnson
JNJNYSE
Johnson & Johnson rose 44.3% from $194.39 to $280.41, ahead of the S&P 500's +11.2%. Its worst day was Oct 13 (−5.7%), and its low came Nov 12 at $194.39.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $2.46 missed the $2.47 estimate on $24.6B revenue (est. $24.2B); FY revenue guidance of $100.0B–$101.0B against the $98.7B consensus.
−0.1% · S&P 500 +1.2%
Story events cover the past 12 months · Times ET
EPS of $2.70 beat the $2.67 estimate on $24.1B revenue (est. $23.5B); FY revenue guidance of $100.3B–$101.3B against the $100.5B consensus.
+0.9% · S&P 500 +1.2%
Johnson & Johnson shares rose 4.0%, while the S&P 500 fell 0.7%.
+4.0%, the year's best day · S&P 500 −0.7%
EPS of $2.90 beat the $2.85 estimate on $25.3B revenue (est. $25.0B); FY revenue guidance of $100.8B–$101.4B against the $100.9B consensus.
−2.7% · S&P 500 +0.4%
Johnson & Johnson shares fell 3.7%, while the S&P 500 rose 1.7%.
−3.7% · S&P 500 +1.7%
Johnson & Johnson shares rose 3.3%, while the S&P 500 fell 0.7%.
+3.3% · S&P 500 −0.7%
EPS of $2.59 beat the $2.53 estimate on $25.4B revenue (est. $25.4B); FY revenue guidance of $101.0B–$101.4B against the $101.3B consensus.
−5.7%, the year's worst day · S&P 500 0.0%
Johnson & Johnson (NYSE: JNJ) today announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 Annual Meeting in Busan, South Korea.
+3.8% · S&P 500 −1.2%
Johnson & Johnson shares rose 3.8%, while the S&P 500 rose 1.7%.
+3.8% · S&P 500 +1.7%
Where it ended: a close of $280.41 on Nov 11, 2026. Up next: Q4 2026 earnings on Jan 20, 2027 (EPS est. $2.91, revenue est. $26.4B).
As of the Nov 11, 2026 close
Replay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for JNJ and SPY from Benzinga historical bars. Not investment advice.
